Corporate digest
Singapore eDevelopment
CATALIST-LISTED Singapore eDevelopment (SeD) on Tuesday said its US subsidiary, Impact BioMedical, has tested two compounds that can successfully inhibit infection by the Covid-19 virus. Results from Impact BioMedical's recent molecular-docking studies indicate that compounds Linebacker and Equivir are able to block three integral viral mechanisms for Sars-CoV-2 (the virus behind Covid-19) replication and infection, said SeD.
IREIT Global
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.